Delphi Diagnostics Announces New Publication Confirming EAI Predicts Benefit from Weekly Paclitaxel in HR+/HER2− Breast Cancer

This analysis independently validated previous findings and further helps to establish EAI as the first genomic assay shown to predict benefit from a contemporary taxane-based chemotherapy regimen in HR+/HER2− breast cancer. For a PDF of this press release, click here HOUSTON, June 22,...